Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
Werewolf Shares Climb As Initial-Stage Solid Tumors Study Kicks-off
Werewolf Therapeutics (NASDAQ: HOWL) has initiated patient dosing in a Phase 1/1b clinical trial evaluating WTX-124, its lead INDUKINET molecule targeting IL-2 for the treatment of solid tumors.
91 Biggest Movers From Friday
Gainers
RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
SVB Leerink Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $17
SVB Leerink analyst Daina Graybosch maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $18 to $17.
80 Biggest Movers From Yesterday
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume.
Mid-Morning Market Update: Markets Edge Lower; US Wholesale Inventories Rise 2.5% In February
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping 100 points on Friday.
53 Biggest Movers From Yesterday
Gainers
MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.